Eli Lilly’s (NYSE:LLY) recent 50% price cut for the two lowest doses of its weight loss drug Zepbound for self-paying customers has coincided with increased costs for some patients using the ...

Aug. 27, 2024 – The maker of the weight loss drug Zepbound is offering the drug at a reduced price for people willing to buy it directly from the company in vials, rather than auto-injector pens ...

Novo Nordisk Shares Surge Following Wegovy Price Cut Announcement. Story by Camilla Jessen ... Eli Lilly reduced the cost of its lower-dose Zepbound vials by $50 for cash-paying customers through ...

Eli Lilly will now sell cheaper vials of Zepbound, ... Lilly’s announcement also presents ... Page 5 of the New York edition with the headline: Weight Loss Medication Is Getting a Price Cut ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints.

Eli Lilly (NYSE:LLY) shares edged around 0.7% lower Tuesday as the company announced a price cut for its obesity drug Zepbound. The new single-dose vials, available in 2.5 mg and 5 mg doses, are ...

Dr. Sterling Elliott, a clinical pharmacist at Northwestern Medicine and assistant professor of orthopedics at Northwestern Feinberg School of Medicine, joins Lisa Dent to explain what you need to ...

Cigna now offers employers $200 Wegovy, Zepbound copay option. The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Trump calls out weight-loss drugs as target of price-cut push. By Deena Beasley. May 12, 2025 9:17 PM UTC ... , opens new tab, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a ...

LLY applied the price cut only to 2.5 mg and 5.0 mg doses of Zepbound available on its direct-to-consumer platform, LillyDirect, for patients willing to pay for the drug themselves.

Eli Lilly (NYSE:LLY) shares edged around 0.7% lower Tuesday as the company announced a price cut for its obesity drug Zepbound. The new single-dose vials, available in 2.5 mg and 5 mg doses, are ...